Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 15Recurrence 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1SCLC, Extensive Stage 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Medulloblastoma 1Lung 1Leukemia 1Head and Neck Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Extensive Stage Lung Small Cell Cancer 1Extensive Small Cell Lung Cancer 1Ependymoma 1ES-SCLC 1Carcinoma, Squamous Cell 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Extensive Stage Lung Small Cell Cancer × Etoposide × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡